Han Xu

SVP, Head of Biotherapeutics

Torrent Pharmaceuticals

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Han Xu is the Senior Vice President and Head of Biotherapeutics at Port Therapeutics in the United States. His research interests focus on cell therapy, particularly in optimizing NOT gate receptors and developing tumor-selective immunotherapies. Recent publications include works on T cells targeting tumor antigens and strategies for overcoming immune evasion in head and neck cancers.

Articles (10)

Year:

2024

Year:

2024

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (2)

Rabi Murad

Sanford Burnham Prebys Medical Discovery Institute

UNITED STATES

View details

Agnes Hamburger

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Han Xu

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

High-throughput screen to identify and optimize NOT gate receptors for cell therapy.

NOT gated T cells that selectively target EGFR and other widely expressed tumor antigens.

A rational approach to assess off-target reactivity of a dual-signal integrator for T cell therapy.

The Tmod cellular logic gate as a solution for tumor-selective immunotherapy.

Genomic Immune Evasion: Diagnostic and Therapeutic Opportunities in Head and Neck Squamous Cell Carcinomas

A carcinoembryonic antigen-specific cell therapy selectively targets tumor cells with HLA loss of heterozygosity in vitro and in vivo.

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers.

Extensive functional comparisons between chimeric antigen receptors and T cell receptors highlight fundamental similarities.

Re-examination of MAGE-A3 as a T-cell Therapeutic Target.

A multivariate, quantitative assay that disentangles key kinetic parameters of primary human T cell function in vitro

Collaborators (2)

Rabi Murad

Agnes Hamburger

Make your next move.